Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation.


Journal

Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967

Informations de publication

Date de publication:
May 2020
Historique:
received: 12 12 2019
accepted: 17 12 2019
pubmed: 21 3 2020
medline: 25 4 2020
entrez: 21 3 2020
Statut: ppublish

Résumé

A few scores predicting the short-term risk of mortality in Systemic sclerosis (SSc) have been reported to date. Our study aimed to create a predictive 15-year all-cause mortality score at the time of the diagnosis of SSc. The study was based on the Spanish Scleroderma Registry (RESCLE). The cohort was split up in derivation (DC) and validation cohort (VC). A multivariate analysis to detect variables related to all-cause mortality within the first 15 years from SSc diagnosis was performed, assigning points to the rounded beta values to create the score (RESCLESCORE). 1935 SSc patients were included. The variables in the final model were as follows: age at diagnosis (+2 points > 65 years-old), male gender (+1 point), lcSSc subset (-1 point), mode of onset other than Raynaud's (+1 point), cancer (+1 point) and visceral involvement, such as ILD (+1 point), PAH (+1 point), heart (+1 point) and renal involvement (+2 points). Autoantibodies did not achieve statistical significance in the multivariate analysis. The 3 categories of risk to predict 15-year all-cause mortality at the time of diagnosis were as follows: low risk (5% vs. 7%, p = .189), intermediate risk (26.5% vs. 25.5%, p = .911) and high risk (47.8% vs. 59%, p = .316). The AUC was 0.799 (DC) vs. 0.778 (VC) (p = .530). In conclusion, the RESCLESCORE demonstrated an excellent ability to categorize SSc patients at the time of diagnosis in separate 15-year all-cause mortality risk strata at the time of diagnosis.

Identifiants

pubmed: 32194200
pii: S1568-9972(20)30059-8
doi: 10.1016/j.autrev.2020.102507
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102507

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflicts of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Auteurs

Manuel Rubio-Rivas (M)

Autoimmune Diseases Unit, Department of Internal Medicine, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: mrubio@bellvitgehospital.cat.

Xavier Corbella (X)

Autoimmune Diseases Unit, Department of Internal Medicine, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Group of Evaluation of Health Determinants and Health Policies, Hestia Chair in Integrated Health and Social Care, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.

Alfredo Guillén-Del-Castillo (A)

Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Carles Tolosa Vilella (C)

Department of Internal Medicine, Corporación Sanitaria Universitaria Parc Taulí, Sabadell, Barcelona, Spain.

Dolores Colunga Argüelles (D)

Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.

Ana Argibay (A)

Unit of Systemic Autoimmune Diseases and Thrombosis, Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain.

José Antonio Vargas Hitos (JA)

Department of Internal Medicine, Hospital Universitario Virgen de las Nieves, Granada, Spain.

José Antonio Todolí Parra (JA)

Department of Internal Medicine, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Cristina González-Echávarri (C)

Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain.

Norberto Ortego-Centeno (N)

Inst Invest Biosanitaria Ibs Granada, Department of Internal Medicine, Unit of Systemic Autoimmune Diseases, Department of Medicine, Facultad de Medicina, Hospital Universitario San Cecilio, Granada, Spain.

Luis Trapiella Martínez (L)

Unit of Systemic Autoimmune Diseases, Department of Internal Medicine, Hospital de Cabueñes, Gijón, Asturias, Spain.

Mónica Rodríguez Carballeira (M)

Department of Internal Medicine, Hospital Universitario Mútua Terrassa, Terrassa, Barcelona, Spain.

Adela Marín Ballvé (A)

Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.

Xavier Pla Salas (X)

Unit of Systemic Autoimmune Diseases, Department of Internal Medicine, Consorci Hospitalari de Vic, Vic, Barcelona, Spain.

Isabel Perales Fraile (I)

Department of Internal Medicine, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain.

Antonio-J Chamorro (AJ)

Department of Internal Medicine, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.

Ana Belén Madroñero Vuelta (AB)

Department of Internal Medicine, Hospital General San Jorge, Huesca, Spain.

Mayka Freire (M)

Department of Internal Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain.

Manuel Ruiz Muñoz (M)

Department of Internal Medicine, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.

Andrés González García (A)

Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Isaac Pons Martín Del Campo (I)

Department of Internal Medicine, Xarxa Assistencial Universitària de Manresa, Manresa, Barcelona, Spain.

María Esther Sánchez García (ME)

Department of Internal Medicine, Hospital Universitario Virgen de Valme, Sevilla, Spain.

David Bernal Bello (D)

Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain.

Gerard Espinosa (G)

Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain.

Francisco José García Hernández (FJ)

Department of Internal Medicine, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Luis Sáez Comet (L)

Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain.

Juan José Ríos Blanco (JJ)

Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain.

Rafael Ángel Fernández de la Puebla Giménez (RÁ)

Department of Internal Medicine, Hospital Universitario Reina Sofía, Córdoba, Spain.

Sabela Sánchez Trigo (S)

Department of Internal Medicine, Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain.

Vicent Fonollosa Pla (V)

Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Carmen Pilar Simeón Aznar (CP)

Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH